ArticleScientific reports2020
Clustering of Alzheimer's and Parkinson's disease based on genetic burden of shared molecular mechanisms.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Oral Dysbiosis and Neuroinflammation: Implications for Alzheimer's, Parkinson's and Mood Disorders.Microorganisms · 2026Review
- Single-cell analysis reveals shared and distinct molecular signatures in brain organoid models of neurodegeneration and neuroinflammation.Alzheimer's research & therapy · 2025Article
- Leveraging Alzheimer's Disease Omics to Identify Pleiotropic Genes Contributing to Neurodegeneration in Primary Open-Angle Glaucoma.Molecular neurobiology · 2025Article
- The STAR collaborative nonsuicidal self-injury study: methods and sample description of the face-to-face sample.Child and adolescent psychiatry and mental health · 2024Article
- Progression subtypes in Parkinson's disease identified by a data-driven multi cohort analysis.NPJ Parkinson's disease · 2024Article
- Genetic-based patient stratification in Alzheimer's disease.Scientific reports · 2024Article
- Identifying Progression-Specific Alzheimer's Subtypes Using Multimodal Transformer.Journal of personalized medicine · 2024Article
- Unbiased classification of the elderly human brain proteome resolves distinct clinical and pathophysiological subtypes of cognitive impairment.Neurobiology of disease · 2023Article
- Multi-omic integration via similarity network fusion to detect molecular subtypes of ageing.Brain communications · 2023Article
- Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective.Animal models and experimental medicine · 2022Review
- Genetics in parkinson's disease: From better disease understanding to machine learning based precision medicine.Frontiers in molecular medicine · 2022Review
- Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease.Frontiers in neurology · 2022Review
- Comprehensive subtyping of Parkinson's disease patients with similarity fusion: a case study with BioFIND data.NPJ Parkinson's disease · 2021Article
- Caution, "normal" BMI: health risks associated with potentially masked individual underweight-EPMA Position Paper 2021.The EPMA journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
One of the visions of precision medicine has been to re-define disease taxonomies based on molecular characteristics rather than on phenotypic evidence. However, achieving this goal is highly challenging, specifically in neurology. Our contribution is a machine-learning based joint molecular subtyping of Alzheimer's (AD) and Parkinson's Disease (PD), based on the genetic burden of 15 molecular mechanisms comprising 27 proteins (e.g. APOE) that have been described in both diseases. We demonstrate that our joint AD/PD clustering using a combination of sparse autoencoders and sparse non-negative matrix factorization is reproducible and can be associated with significant differences of AD and PD patient subgroups on a clinical, pathophysiological and molecular level. Hence, clusters are disease-associated. To our knowledge this work is the first demonstration of a mechanism based stratification in the field of neurodegenerative diseases. Overall, we thus see this work as an important step towards a molecular mechanism-based taxonomy of neurological disorders, which could help in developing better targeted therapies in the future by going beyond classical phenotype based disease definitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.